Overview
PT-141 (bremelanotide, brand name Vyleesi) is the rare peptide that made it all the way to FDA approval — for hypoactive sexual desire disorder in premenopausal women. It was developed directly from Melanotan 2 research, after the tanning peptide kept producing unexpected sexual effects in trial subjects.
Unlike PDE5 inhibitors (Viagra, Cialis), which work on blood vessels, PT-141 works on the brain — desire itself, not just mechanics.
How It Works
PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus, a key node in the neural circuitry of sexual desire and arousal. This central mechanism means it can increase desire and arousal regardless of vascular function.
A different kind of drug
Because it works centrally, it is effective in women (its approved population) and in men whose issues are desire-based rather than vascular. Effects begin 45-60 minutes after injection and can last several hours.
Key Benefits
Increased sexual desire — the approved effect, demonstrated in phase 3 trials in women.
Arousal in men — off-label use is common, including in cases where PDE5 inhibitors fail.
Central mechanism — works on desire, complementing rather than duplicating vascular drugs.
Real regulatory pedigree — actual human safety data exists, a rarity in the peptide world.
Side Effects & Considerations
Nausea is very common — around 40% in trials — along with flushing and headache. A transient blood pressure increase (with slight heart rate decrease) led to the recommendation of no more than one dose per 24 hours and 8 per month.
Practical notes
Hyperpigmentation of gums and skin can occur with frequent use. The approved product is a legitimate prescription medication; grey-market PT-141 carries the usual purity questions. For men, combining with PDE5 inhibitors is common practice but should be discussed with a physician given the blood pressure effects.
Dosage protocols
| Protocol | Dosage | Frequency | Duration | Notes |
|---|---|---|---|---|
| Approved (Vyleesi) | 1.75 mg | As needed, 45-60 min before activity | Max 1 dose per 24h, 8 per month | Subcutaneous into abdomen or thigh. Prescription only. |
Warnings
Prescription medication. Frequent nausea. Transient blood pressure increase — respect the dosing limits. Hyperpigmentation with frequent use.